title: The significant role of membrane stabilization in hypothermic cardioplegic cardiac preservation in a canine experimental model.
abstract: Isolated mongrel hearts were preserved for 6 h at 5 degrees C followed by normothermic reperfusion for 2 h. The dogs were divided into three groups; K+-cardioplegic solution alone, group C, n = 7; K+-cardioplegic solution with lidocaine 200 mg/l, group L, n = 7; and K+-cardioplegic solution with betamethasone 250 mg/l and lidocaine 200 mg/l, group B + L, n = 7. Ventricular fibrillation occurred early during reperfusion in all dogs in group C, in one of seven in group L, and in two of seven dogs in group B + L. The serum MB fraction of creatinine kinase (MB-CK), mitochondrial aspartate aminotransferase (m-AAT) and calcium overload were suppressed to a greater extent in both groups L and B + L during reperfusion compared to group C. Myocardial ATP, total adenine nucleotide, and creatine phosphate did not differ between the three groups at the end of reperfusion. Myocardial ADP and AMP declined significantly during reperfusion in group C, however, they remained unchanged in group B + L and increased in group L which showed significantly higher levels compared to group C. Left ventricular functional recovery during reperfusion was consistently better in both group L and B + L compared to group C. These results suggested that membrane stabilization prevents myocardial damage from hypothermia and cardioplegia and provides better myocardial viability and functional recovery in donor heart preservation.
authors: Department of Thoracic-Cardiovascular Surgery, Tokyo Medical and Dental University, School of Medicine, Tokyo, Japan.
authors: M
authors: M
authors: Sunamori
authors: I
authors: I
authors: Sultan
authors: T
authors: T
authors: Shirai
authors: A
authors: A
authors: Suzuki
mesh_terms: D000818:Animals; D001623:Betamethasone / Q000494:pharmacology; D015415:Biomarkers / Q000032:analysis; D002118:Calcium / Q000502:physiology; D002314:Cardioplegic Solutions / Q000494:pharmacology*; D003402:Creatine Kinase / Q000032:analysis; D052279:Creatine Kinase, MB Form; D004285:Dogs; D006321:Heart / Q000187:drug effects; D007425:Intracellular Membranes / Q000187:drug effects / Q000648:ultrastructure*; D007527:Isoenzymes / Q000032:analysis; D008012:Lidocaine / Q000494:pharmacology*; D008933:Mitochondrial Swelling; D023421:Models, Animal; D009206:Myocardium / Q000648:ultrastructure*; D009926:Organ Preservation / Q000379:methods*; D014693:Ventricular Fibrillation / Q000209:etiology
chemical_list: D015415:Biomarkers; D002314:Cardioplegic Solutions; D007527:Isoenzymes; D001623:Betamethasone; D008012:Lidocaine; D003402:Creatine Kinase; D052279:Creatine Kinase, MB Form; D002118:Calcium